Our study in multiple independent cohorts found that compared to TP53 WT, only TP53 CD-SC was able to suggest better OS in GC patients, while patients with TP53 C-LOH had similar survival outcomes as TP53 WT patients. This evidence concerns the gene TP53 and gastric cancer.